Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CICLOPIROX vs AMPHOTEC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Topical treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis,Treatment of seborrheic dermatitis of the scalp,Treatment of cutaneous candidiasis (moniliasis) due to Candida albicans,Treatment of onychomycosis of fingernails and toenails due to Trichophyton rubrum,Off-label: Treatment of tinea versicolor, vaginal candidiasis, and superficial dermatophyte infections
Treatment of progressive, potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis,Treatment of visceral leishmaniasis (off-label),Empiric therapy in febrile neutropenic patients (off-label),Treatment of primary amebic meningoencephalitis (off-label)
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Minimal systemic absorption following topical application. The small absorbed fraction is primarily metabolized via glucuronidation and oxidation. Unchanged drug and metabolites are excreted renally and fecally. Specific hepatic enzymes involved are not well characterized.
Metabolized minimally, if at all; elimination is primarily via unchanged drug excretion in urine and bile over a prolonged period.
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
94-98% bound to plasma proteins, primarily albumin
>95% bound to albumin and alpha-1-acid glycoprotein.
1.2-2.0 L/kg, indicating extensive tissue distribution
4.0 L/kg (large, indicates extensive tissue binding, especially in liver, spleen, and lungs).
Topical: minimal systemic absorption (<1-5% of applied dose); oral: not formulated for systemic use
Not applicable (IV only); if oral, <5% (due to poor absorption and first-pass metabolism).
No specific dose adjustments are recommended; systemic absorption is minimal (<1.3%) with topical application. For oral use (not available in the US), no data for renal impairment.
No dose adjustment required for renal impairment; however, monitor renal function closely during therapy.
No dose adjustments needed for topical use due to negligible systemic absorption. No data for oral formulations.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
Ciclopirox 1% cream: Approved for children ≥10 years with tinea pedis or tinea corporis; apply twice daily for 2 weeks. Ciclopirox 8% nail lacquer: Not recommended in children <12 years. Ciclopirox 1% shampoo: Not established in children <16 years.
5 mg/kg intravenously once daily; safety and efficacy not established in neonates.
No specific dose adjustments; topical use has minimal systemic absorption. Consider skin thinning and increased risk of irritation in elderly; use caution with prolonged application.
No specific dose adjustment; monitor renal function and electrolyte levels due to age-related decline in renal function.
None currently listed in FDA labeling.
This drug should be used primarily for treatment of patients with progressive, potentially life-threatening fungal infections; it is not intended for treatment of non-invasive fungal infections (e.g., oral thrush, vaginal candidiasis) in patients with normal neutrophil counts.
For external use only; avoid contact with eyes and mucous membranes,If irritation or sensitivity develops, discontinue treatment,Not for intravaginal or ophthalmic use,Use in diabetic patients may require additional monitoring for nail infections,Keep away from heat and open flame (ciclopirox solution contains alcohol)
Nephrotoxicity: monitor renal function closely; risk increased with concurrent nephrotoxic drugs.,Infusion-related reactions: fever, chills, rigors, hypotension, dyspnea; premedicate as needed.,Electrolyte abnormalities: hypokalemia, hypomagnesemia; monitor levels and replace.,Hepatotoxicity: monitor liver function tests.,Cardiotoxicity: arrhythmias, especially with rapid infusion or hypokalemia.,Pulmonary toxicity: acute pulmonary edema (rare), especially in patients with low ejection fraction.
Hypersensitivity to ciclopirox or any component of the formulation
Hypersensitivity to amphotericin B or any component of the formulation (unless condition is life-threatening and amenable only to amphotericin therapy).
No significant food interactions have been reported with topical ciclopirox. For oral ciclopirox (not available in the US), food may affect absorption; consult prescribing information.
No specific food interactions. Ensure adequate hydration and electrolyte intake as directed. Avoid grapefruit juice as it may alter drug metabolism.
Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity in rats or rabbits. For topical use, there is no evidence of teratogenicity in humans. However, sufficient data are lacking for first trimester risk. The drug should be used during pregnancy only if clearly needed, with caution primarily in first trimester.
Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use during the first trimester is not associated with a significant increase in congenital anomalies. During the second and third trimesters, there is no evidence of fetal toxicity, although the drug should be used only if clearly needed due to maternal systemic fungal infection.
It is unknown if ciclopirox is excreted in human milk. Due to low systemic absorption after topical application, the amount ingested by a nursing infant is likely negligible. Use with caution on small areas and avoid application to breast. M/P ratio not established.
Amphotericin B is excreted into breast milk in low concentrations. The M/P ratio is unknown. It is considered compatible with breastfeeding because of poor oral bioavailability; however, caution is advised, and monitoring for infant diarrhea or thrush is recommended.
No pharmacokinetic changes requiring dose adjustment have been reported for topical ciclopirox. Systemic absorption is minimal and pregnancy-induced changes in skin permeability or clearance are not expected to alter systemic exposure significantly. Standard topical dosing (apply twice daily to affected areas) is appropriate.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustment. Standard dosing is 3-5 mg/kg/day IV, but serum concentrations should be monitored to ensure therapeutic levels without excessive toxicity. Dose may need to be increased by 25-50% in the third trimester.
Apply topical ciclopirox once or twice daily, covering the lesion and a 1 cm margin of normal skin. For nail infections, file away loose nail material before applying lacquer. Avoid occlusive dressings unless directed. Treatment duration for tinea pedis is 2 weeks; for tinea corporis/cruris, 2-4 weeks. For onychomycosis, treatment may require 48 weeks or until nail replacement.
Amphotec (amphotericin B liposomal) is the preferred formulation for invasive fungal infections due to reduced nephrotoxicity compared to deoxycholate. Monitor for infusion-related reactions (fever, rigors, hypotension) and premedicate with acetaminophen, diphenhydramine, and hydrocortisone. Requires baseline and serial renal function, electrolytes (especially potassium, magnesium), and liver function tests. Do not use with other nephrotoxic drugs if possible. Electrolyte repletion is critical.
Wash hands before and after applying the medication.,Apply a thin layer to the affected area and rub in gently.,Do not use on open wounds, or in eyes, mouth, or vagina.,For nail lacquer, apply daily over the entire nail plate and to the underside of the nail tip.,Avoid nail polish or artificial nails during treatment.,Complete the full course even if symptoms improve.,Notify your doctor if irritation or allergic reaction occurs.
This medication treats serious fungal infections and is given intravenously in a hospital setting.,You may experience fever, chills, or shaking during the infusion; these can be managed with premedications.,Kidney function and blood electrolyte levels will be monitored regularly.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or symptoms of electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,Avoid taking other medications that can harm the kidneys (e.g., certain antibiotics, NSAIDs) without consulting your doctor.
"Combining ciclopirox, an antifungal agent, with benidipine, a calcium channel blocker, may result in increased toxicity or reduced therapeutic efficacy. Benidipine is metabolized via CYP3A4; ciclopirox can inhibit CYP3A4, potentially raising benidipine plasma concentrations and causing hypotension, dizziness, or peripheral edema. Additionally, ciclopirox may have additive cardiodepressant effects, leading to bradycardia or worsening heart failure in susceptible patients."
"Co-administration of Ciclopirox and Eperisone may lead to additive antagonism of normal muscle tone and coordination due to concurrent central nervous system depression. Ciclopirox, primarily used for dermatological conditions, has noted sedative effects from systemic absorption, while Eperisone centrally acts as a muscle relaxant with sedative properties. The combined use can potentiate drowsiness, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents."
"Losartan, an angiotensin II receptor blocker, and ciclopirox, a topical antifungal, are not expected to have a clinically significant pharmacokinetic interaction. Ciclopirox is minimally absorbed through the skin (<0.01% of applied dose) and undergoes hepatic glucuronidation and renal excretion. Losartan is metabolized primarily by CYP2C9 and CYP3A4 to its active metabolite. The baseline statement suggests a theoretical inhibition of ciclopirox metabolism by losartan, but given ciclopirox's negligible systemic exposure after topical use and different metabolic pathways, this interaction is unlikely to produce adverse clinical outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CICLOPIROX vs AMPHOTEC, answered by our medical review team.
CICLOPIROX is a Antifungal that works by Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.. AMPHOTEC is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CICLOPIROX and AMPHOTEC depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CICLOPIROX is: Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).. The standard adult dose of AMPHOTEC is: Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CICLOPIROX and AMPHOTEC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CICLOPIROX is classified as Category A/B. Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity i. AMPHOTEC is classified as Category C. Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.